AASLD2016[72]临床结果为慢性具有可比性 乙肝患者使用口服病毒

StephenW

72
Clinical outcomes were comparable between chronic
hepatitis B patients with virological response using oral
antiviral therapy and inactive carriers when adjusting
for fibrotic burden
Hye Soo Kim1, Beom Kyung Kim2, Seung Up Kim2, Jun Yong Park2,
Do Young Kim2, Sang Hoon Ahn2, Kwang-Hyub Han2; 1Yonsei
University College of Medicine, Seoul, Korea (the Republic of);
2Department of Internal Medicine, Yonsei University College of
Medicine, Seoul, Korea (the Republic of)
Background/aims: We aimed to compare the risk of developing
hepatocellular carcinoma (HCC) between patients with
chronic hepatitis B (CHB) who achieved virological response
(VR) by nucleos(t)ide analogues (NUC-VR group) and patients
with inactive CHB phase (ICHB group), after adjusting for
fibrotic burden by liver stiffness (LS) using transient elastography.
Methods: To adjust for imbalances between the NUC-VR
group (HBV-DNA < 2,000 IU/mL) (n=1,964) and the ICHB
group (n=825), propensity-score matching (PSM) was performed
at a 1:1 ratio, based upon the following: 1) age,
gender, diabetes, platelet count, albumin, and total bilirubin
as well as ultrasonographic cirrhosis (PSM model-1), 2) the
above 6 variables and LS (PSM model-2), and 3) the above
6 variables, LS, and ultrasonographic cirrhosis (PSM model-
3). The cumulative rates of HCC development were assessed
using Kaplan-Meier analysis and compared using the Klein and
Moeschberger method. Results: Among the study population,
PSM resulted in 728, 739, and 724 pairs for PSM model-1,
PSM model-2, and PSM model-3, respectively. The cumulative
rates of HCC development at 7 years between the NUC-VR
and ICHB groups were similar in all models (7.9% vs. 10.8%
by PSM model-1, 6.5% vs. 10.4% by PSM model-2, and 7.9%
vs. 10.8% by PSM model-3, all p > 0.05). When PSM was
performed in sub-cohorts with and without ultrasonographic cirrhosis
using PSM model-2, the cumulative rates of HCC development
at 7 years also remained similar between the NUC-VR
and ICHB groups (all p > 0.05). Conclusions: The NUC-VR
group has a similar risk of HCC development compared to the
ICHB group after properly adjusting for fibrotic burden.
Disclosures:
The following people have nothing to disclose: Hye Soo Kim, Beom Kyung Kim,
Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub
Han

StephenW

72
AASLD2016 [72]临床结果为慢性具有可比性
乙肝患者使用口服病毒学应答
抗病毒治疗和非活动性携带者调整时
对于纤维化负担
临床结果为慢性具有可比性
乙肝患者使用口服病毒学应答
抗病毒治疗和非活动性携带者调整时
对于纤维化负担
惠洙Kim1，范庆Kim2，升向上Kim2，君永PARK2，
难道年轻Kim2，桑勋Ahn2，刘广Hyub韩; 1Yonsei
医药，韩国首尔（共和国）的大学;
内科，延世大学学院教研室
医药，韩国首尔（共和国）
背景/目标：我们的目的是比较发展中的风险
患者之间肝细胞癌（HCC）
慢性乙型肝炎（CHB）谁取得病毒学应答
（VR）由核苷（酸）类似物（NUC-VR组）和病人
非活动CHB阶段（ICHB组），后调整
通过使用瞬时弹性成像肝脏硬度（LS）纤维化的负担。
方法：调整为NUC-VR之间的不平衡
组（HBV-DNA <2000 IU / mL）的（N = 1964）和ICHB
组（n = 825），进行倾向得分匹配（PSM）
以1：1的比例，基于以下几点：1）年龄，
性别，糖尿病，血小板计数，白蛋白和总胆红素
以及超声波诊断肝硬化（PSM模型-1），2）的
上述6个变量和LS（PSM模型-2），和3）将上述
6个变量，LS和超声肝硬化（PSM建模
3）。肝癌发展的累积利率进行了评估
采用Kaplan-Meier分析，并使用克莱因和比较
Moeschberger方法。结果：在研究人群中，
PSM导致728，739，和724双为PSM模型1，
PSM模型-2，和PSM模型-3，分别。累积
在NUC-VR之间7年肝癌的发展速度
和ICHB组在所有车型相似（7.9％比10.8％
通过PSM模型-1，6.5％对通过PSM模型-2 10.4％，和7.9％
与由PSM模型3 10.8％，均P> 0.05）。当PSM是
子队列使用和不使用超声肝硬化进行
使用PSM模型2，肝癌发展的累积率
7年时也保持了NUC-VR相似
和ICHB组（均P> 0.05）。结论：NUC-VR
集团也有类似的HCC发展的风险相比，
经过适当调整纤维化负担ICHB组。
披露：
下面的人都没有透露：惠洙金，范庆金，
升最多金，勇俊园，难道扬金，桑勋安，刘广Hyub
韩